The publication of preclinical data of the CD39-blocking monoclonal antibody IPH5201 appears in the May 21, 2019 issue of the journal Cell Reports. 

Read the full manuscript titled “Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies

27 July 2019

Anti-CD39 mAb publication in Cell Reports
27 July 2019

The publication of preclinical data of the CD39-blocking monoclonal antibody IPH5201 appears in the May 21, 2019 issue of the journal Cell Reports.  Read the full manuscript titled “Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies”
[ Read more ]
17 June 2019

Meet us at the 2019 ASCO annual meeting in Chicago
17 June 2019

Jeremy BASTID, Chief Operating Officer, will attend the ASCO annual meeting to be held in Chicago, IL, May 31 – June 4, 2019.
[ Read more ]
17 November 2018

Meet us at the 2018 Bio Europe meeting in Copenhagen
17 November 2018

Gilles Alberici, CEO, will attend the 2018 BIO-Europe meeting to be held in Copenhagen on November 2018, 5th to 7th.
[ Read more ]
27 October 2018

PRESS RELEASE – IL-17 patent granted in Europe
27 October 2018

Press Release Lyon, October 8, 2018 Interleukin-17 patent granted in Europe Lyon, France, October 8, 2018 – OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announced the grant of patent EP2569335 by the European Patent Office. This patent covers IL-17A neutralizing antibodies for use as a therapeutic tool to increase the response to other chemotherapeutic agents. “The delivery of this European Patent is another important milestone for OREGA Biotech; it is the fifth issued patent related to our IL‑17 programs”, commented Jeremy Bastid, Chief Operating Officer of OREGA Biotech. “Intellectual property is a key asset in OREGA’s target discovery programs. Our capacity to obtain broad claims covering novel cancer targets offers a valuable competitive advantage.” Read the press release.
[ Read more ]